Результаты поиска

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Repurposing Disulfiram as an Anti-Obesity Drug: Treating and Preventing Obesity in High-Fat-Fed Rats.

Background and objectivesA drug repurposing strategy is an approach for identifying new therapeutic uses for approved or investigational drugs. Thanks to the moderate cost of repurposing a drug compared to bringing new chemical entity to the market, drug repurposing is rapidly gaining ground. The aim of this work is to study the anti-obesity effect of disulfiram (DSF), an irreversible aldehyde dehydrogenase inhibitor approved by the Food and Drug Administration (FDA) to treat chronic alcoholism since 1951.MethodsThirty male Albino rats were randomly assigned to six groups. G1, the control grou

Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.

The field of gene therapy is striving more than ever to define a path to the clinic and the market. Twenty gene therapy products have already been approved and over two thousand human gene therapy clinical trials have been reported worldwide. These advances raise great hope to treat devastating rare and inherited diseases as well as incurable illnesses. Understanding of the precise pathomechanisms of diseases as well as the development of efficient and specific gene targeting and delivery tools are revolutionizing the global market. Currently, human cancers and monogenic disorders are indicati

Сердечно-сосудистые заболевания

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Escherichia coli in the production of biopharmaceuticals.

Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. Although E. coli has some disadvantages, such as lack of post-translational modifications and toxicity, it is an important host with advantages such as bei

Совпадение в полном тексте источника
… vein occlusion following macular edema, and myopic choroidal neovascularization. 66 , 90 Susvimo (ranibizumab), a VEGF inhibitor, is produced by Genentech in E. coli and was approved by the FDA for AMD in 2021. 91 Trastuzumab (Herceptin) monoclonal antibody was produced by Genentech/Roche in Chinese … Byooviz | A biosimilar ranibizumab molecule | AMD, retinal vein occlusion following macular edema, and myopic choroidal neovascularization | It has a similar mechanism of action to Lucentis. Susvimo | Ranibizumab | Neovascular (wet) AMD | It targets the VEGF‐A protein and blocks its action. …

The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases.

PurposeIn 2007 the two senior authors wrote a review on the structure and function of the endothelial glycocalyx layer (Weinbaum in Annu Rev Biomed Eng 9:121-167, 2007). Since then there has been an explosion of interest in this hydrated gel-like structure that coats the luminal surface of endothelial cells that line our vasculature due to its important functions in (A) basic vascular physiology and (B) vascular related diseases. This review will highlight the major advances that have occurred since our 2007 paper.MethodsA literature search mainly focusing on the role of the glycocalyx in the

17th Конгресс ЕВНОС: Милан, Италия, 4–6 Июнь, 2026 года

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Разнообразие по признаку пола 90-Day Послеоперационные осложнения у пациентов с анемической атропластикой.

Первичная анемия представляет собой фактор риска для неблагоприятных последствий после полной артропопластики (THA), что в непропорционально большой степени сказывается на женщинах и способствует заболеваемости. Хотя как анемия, так и пол независимо связаны с постоперационными осложнениями, лишь в немногих исследованиях анализировались результаты у анемических пациентов, стратифицированных по признаку пола. По сравнению с этим исследованием 90-day Коэффициент осложнений послеоперационного периода между анемическими пациентами мужского пола и анемическими пациентами женского пола, проходящими п

Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?

Multiple organ dysfunction syndrome (MODS) occurs in response to major insults such as sepsis, severe haemorrhage, trauma, major surgery and pancreatitis. The mortality rate is high despite intensive supportive care. The pathophysiological mechanism underlying MODS are not entirely clear, although several have been proposed. Overwhelming inflammation, immunoparesis, occult oxygen debt and other mechanisms have been investigated, and - despite many unanswered questions - therapies targeting these mechanisms have been developed. Unfortunately, only a few interventions, usually those targeting mu

2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

An Italian cartography of VEXAS-related thrombosis.

Thrombotic events (TEs) occur in up to 40% of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome, but data on its clinical-genomics features and anticoagulation strategies are limited. To gain more insight into this, we conducted a two-step study evaluating the prevalence and outcome of TE in VEXAS. First, among 1086 patients followed for TEs, 198 were men aged >40 years with unprovoked thrombosis and no known thrombophilia; 21 also had at least one VEXAS-compatible feature and underwent UBA1 exon 3 testing. No UBA1 mutation was detected in these 21 pat

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to nove

Совпадение в полном тексте источника
… Ophthalmoscopic examination of the fundus can reveal characteristic findings of hyperviscosity, such as the presence of dilated and tortuous retinal veins, flame-shaped hemorrhages, edema of the papilla, and retinal exudates. … Although uncommon, there may be central retinal vein occlusion and retinal detachment ( 92 ).Once the diagnosis is established (or if suspicion is high), emergent therapy with plasma exchange is imperative. …

Histone deacetylase 6: A new player in oxidative stress‑associated disorders and cancers (Review).

Histone deacetylase 6 (HDAC6), a distinctive member of the histone deacetylase family, plays a crucial role in regulating the cellular response to oxidative stress. Unlike other HDACs, HDAC6 primarily deacetylates non‑histone proteins, influencing various cellular functions critical to the pathogenesis of numerous oxidative stress‑related diseases. This review summarizes the latest research on how HDAC6 affects oxidative stress pathways and its impact on diseases such as neurodegeneration, cancer and cardiovascular disorders. Additionally, the therapeutic potential of targeting HDAC6, as evide

KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).

The 2026 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease represents a substantial update, coming more than a decade since the previous KDIGO guideline on the topic. This time lapse was necessary in order to accumulate new scientific evidence that was meaningful for an updated guideline. The new guideline now includes updated recommendations and practice points for anaemia management, incorporating recent evidence on intravenous iron therapies and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This European R

Selected abstracts from the XXXVIII National Congress of the Italian Society of Hypertension (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.

Ocular toxicity from anti-cancer drugs is frequently overlooked, largely because it is non-life-threatening, whereas clinical priorities often center on adverse events that pose immediate risks to survival. Antibody-drug conjugates (ADCs) have emerged as an important therapeutic modality in oncology, offering potent cytotoxicity against tumor cells through the targeted delivery of payloads. However, this potency also introduces a spectrum of toxicities, among which ocular toxicity has gained increasing attention. ADC-induced ocular toxicity can impair visual function and significantly compromi

Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

A quarter-century after the discovery of autotaxin in cell culture, the autotaxin-lysophosphatidate (LPA)-lipid phosphate phosphatase axis is now a promising clinical target for treating chronic inflammatory conditions, mitigating fibrosis progression, and improving the efficacy of existing cancer chemotherapies and radiotherapy. Nearly half of the literature on this axis has been published during the last five years. In cancer biology, LPA signaling is increasingly being recognized as a central mediator of the progression of chronic inflammation in the establishment of a tumor microenvironmen

Совпадение в полном тексте источника
… LPA and ATX concentrations are positively correlated with the proinflammatory mediators, IL-6, IL-8, MCP-1 and VEGF in patients with macular edema secondary to retinal vein occlusion [ 119 ], this finding opens the possibility for ATX/LPA targeted therapy. 4.6. … Lysophosphatidic acids and autotaxin in retinal vein occlusion Retina 2016 36 2311 2318 10.1097/IAE.0000000000001112 27648638 120. Udomsinprasert W. Honsawek S. Anomasiri W. Chongsrisawat V. Vejchapipat P. Poovorawan Y. …

Research progress on venous thrombosis development in patients with malignant tumors.

The coexistence of venous thromboembolism (VTE) within patients with cancer, known as cancer-associated thrombosis (CAT), stands as a prominent cause of mortality in this population. Over recent years, the incidence of VTE has demonstrated a steady increase across diverse tumor types, influenced by several factors such as patient management, tumor-specific risks, and treatment-related aspects. Furthermore, mutations in specific genes have been identified as potential contributors to increased CAT occurrence in particular cancer subtypes. We conducted an extensive review encompassing pivotal hi

Antibodies to watch in 2026.

The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics. Since the first article was published in 2010, the late-stage pipeline has grown from 26 antibody therapeutics to over 200, while during the same time numerous molecules in late-stage studies either transitioned to regulatory review and were approved or were terminated. In this installment of the series, we recap first marketing approvals granted to 19 antibody therapeutics in 2025, discuss 26 molecules currently in r

Emergency Care

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.